Abstract library

90 results for "111In-pentetreotide scintigraphy".
#1317 Value of Octreoscan and 18FDG-PET for Clinical Prognosis of Patients with Neuroendocrine Neoplasms
Introduction: Despite the existence of biological markers of aggressiveness, the clinical course of gastro-entero-pancreatic (GEP) neuroendocrine neoplasms (NEN) remains difficult to predict. Discrepancies between imaging data generated with 111In-pentetreotide scintigraphy (SRS) and 18 F-FDG-PET could reflect the degree of cellular de-differentiation.
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Professor Francois Pralong
Authors: Gouffon M, Prior J, Ratib O, Krause T, ...
#760 Intraoperative Gamma Probe Detection of Metastatic Medullary Thyroid Carcinoma (MTC) with 111In-Pentetreotide
Introduction: MTC is a rare thyroid malignancy representing approximately 5-10% of all thyroid tumors. Early diagnosis and radical surgery are essential to reduce the morbidity and mortality associated with MTC. Somatostatin receptors (SSTRs) expression has been described in MTC with a variable pattern, SSTR2 being prevalent. Although somatostatin analogues demonstrated poor efficacy in the control of MTC growth, SSTR expression can be useful in Nuclear Medicine diagnostic procedures. 111In-pentetreotide scintigraphy and 68Ga-somatostatin analogues PET-CT represent valuable techniques in the detection of MTC, although with a lower sensitivity compared to 18F-DOPA PET-CT.
Conference: 10th Annual ENETS Conference (2013)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: Laura De Marinis
Keywords: mtc, srs
#873 The Analysis of Immunohistochemistry Staining, Neuronspecific Enolase (NSE) Level and Somatostatin Receptor Scintigraphy of Gastroenteropancreatic Neuroendocrine Neoplasm Cases
Introduction: 99mTc-HYNIC-TYR3-OCTREOTIDE somatostatin receptor (SSR) scintigraphy has been used to diagnose gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN).
Conference: 11th Annual ENETS Conference (2014)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Jiangyuan Yu
Authors: Yu J, Li J, Yang Z, ...
#2237 99mTc-Colloid Scintigraphy in the Differential Diagnosis of Pancreatic NET
Introduction: An accessory spleen (AS), a benign and congenital condition, is characterized by a small nodule of splenic tissue found outside of the spleen, which can mimic a pancreatic neoplasm (p-NET). 68Ga-PET/CT is used to study lesions suspected for NET, but the radioactive tracer binds also the reticuloendothelial cells, resulting in false positives in case of AS.
Conference: 15th Annual ENETS conference (2018)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: md Sabrina Chiloiro
#35 Primary Hyperparathyroidism in patients with gastric carcinoid Tumors type-1: an unusual coexistence
Introduction: Although a number of familiar endocrine syndromes are associated with primary hyperparathyroidism (PHP), there is no information regarding its prevalence in other sporadic neuroendocrine diseases.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Dimitrios Thomas
#1300 Staging of Neuroendocrine Tumors: Value of Hybrid Imaging With 111In- Pentetreotide
Introduction: Neuroendocrine tumors (NET) are rare and can occur anywhere in the body. Ninety-eight percent of these tumors express the type 2 of somatostatin receptors, making possible the functional imaging of NET. 111In-labelled pentetreotide specifically binds to somatostatin receptors, with particular affinity to subtypes 2 and 5.
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dorra Ben Sellem
#56 Somatostatinreceptor scintigraphy with Tc-99m-tektrotyd in patients with neuroendocrine tumors: correlation with immunohistochemistry
Introduction: Somatostatin receptor scintigraphy (STRS) with Tc-99m-tektrotyd has been used in the past few years for diagnosis and staging of neuroendocrine tumors (NETs). A number of clinicopathologic criteria proved to be useful predictors of malignant behavior of these tumors. Immunohistochemical markers for NETs include cell proliferation (Ki-67 index) and neuroendocrine markers such as chromogranin A (CgA) and synaptophysin.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Prof Margarida Rodrigues
#1048 The Additional Value of Somatostatin Receptor Scintigraphy During Preoperative Staging in Patients with Non-Functioning Pancreatic Neuroendocrine Tumors.
Introduction: During diagnostic workup for non-functioning pancreatic neuroendocrine tumors (NF-pNET) both computed tomography scan (CT-scan) and somatostatin receptor scintigraphy (SRS) are made.
Conference: 12th Annual ENETS Conference (2015)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Anneke Jilesen
#1299 Clinical Value of Somatostatin Receptor Scintigraphy in the Management of Medullary Thyroid Carcinoma
Introduction: Medullary Thyroid Carcinoma (MTC) is a rare form of thyroid cancer. It represents 5 to 10 % of these cancers. MTC grows from specialized thyroid cells called para-follicular cells, or C-cells that secrete a hormone called calcitonin. Its prognosis is usually good. Recurrences can occur, requiring lifelong surveillance.
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dorra Ben Sellem
#2282 Value of Somatostatin Receptor Scintigraphy (SRS) in Patients with Appendiceal Neuroendocrine Neoplasms (ANEN) Based on Clinical Follow-up and Results of NETest
Introduction: Neuroendocrine neoplasms of the appendix (ANEN) are one of the most commonly identified gastroentropancreatic tumours (GEP). The aim of this retrospective study was to review the value of Somatostatin Receptor Scintigraphy (SRS) in staging and imaging follow-up of patients with confirmed ANEN, NENG1 and NENG2 in single institution.
Conference: 15th Annual ENETS conference (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Sonia Konsek